Nyra Medical

Nyra Medical is a clinical-stage medical device innovator targeting the significant unmet need in functional mitral regurgitation (FMR), a condition affecting millions of heart failure patients. Its core technology, CARLEN, is a transcatheter, single-leaflet augmentation device intended to correct regurgitation by enhancing the native leaflet, aiming to preserve natural valve function and treat a broader anatomical range than current edge-to-edge repair (TEER) systems. Led by industry veteran CEO Lori Chmura, the company has completed First-in-Human studies and is preparing for a U.S. Feasibility Study, backed by experienced medtech investors. Nyra aims to capture a portion of the multi-billion dollar transcatheter mitral valve repair market by addressing its current anatomical limitations.

Transcatheter single-leaflet augmentation technology for mitral valve repair. The Cardiac Leaflet Enhancer (CARLEN) is a device designed to be attached to a native mitral valve leaflet to add length and thickness, restoring coaptation without clipping leaflets together, thereby preserving natural valve motion and orifice area.

Nyra operates in the competitive transcatheter mitral valve repair market, dominated by Abbott's MitraClip and Edwards Lifesciences' PASCAL systems (TEER). Its primary competition is these incumbents, but its technology differentiates by targeting a patient subset they cannot treat. Other potential competitors include companies developing transcatheter annuloplasty devices or other novel repair concepts.